Inflammation-induced thrombosis: Mechanisms, disease associations and management

Current Pharmaceutical Design

Volumn 18, Issue 11, 2012, Pages 1478-1493

  Aksu, Kenan ^a   Donmez, Ayhan ^a   Keser, Gokhan ^a  

^a EGE UNIVERSITY SCHOOL OF MEDICINE   (Turkey)

Author keywords

Autoantibody; Beh et disease; Familial mediterranean fever; Inflammation; Platelets; Rheumatic disease; Thrombosis; Vasculitis

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; ADENOSINE DIPHOSPHATE; ADENOSINE TRIPHOSPHATE; ANTITHROMBIN III; AUTOANTIBODY; AZATHIOPRINE; C REACTIVE PROTEIN; COLCHICINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN; DISEASE MODIFYING ANTIRHEUMATIC DRUG; GLUCOCORTICOID; GLUTAMIC ACID; HEPARIN; HYDROXYCHLOROQUINE; ILOPROST; IMMUNOSUPPRESSIVE AGENT; INTERLEUKIN 8; LEFLUNOMIDE; METHOTREXATE; MONOCYTE CHEMOTACTIC PROTEIN 1; OMEGA 3 FATTY ACID; PHOSPHOLIPID ANTIBODY; POLYPHOSPHATE; PRASUGREL; ROFECOXIB; SEROTONIN; TISSUE FACTOR PATHWAY INHIBITOR;

ANCA ASSOCIATED VASCULITIS; ANGIOGENESIS; ANTICOAGULANT THERAPY; ANTIPHOSPHOLIPID SYNDROME; AORTA ARCH SYNDROME; ARTERY THROMBOSIS; ATHEROSCLEROSIS; BEHCET DISEASE; BLOOD CLOTTING; BUERGER DISEASE; CARDIOVASCULAR RISK; CELL INTERACTION; CHLAMYDOPHILA PNEUMONIAE; DISEASE ASSOCIATION; DISEASE DURATION; ENDOTHELIUM; ENDOTHELIUM CELL; ENTERITIS; ETHNICITY; FAMILIAL MEDITERRANEAN FEVER; FIBRINOLYSIS; GENETIC PREDISPOSITION; HEMOSTASIS; HUMAN; HYPERHOMOCYSTEINEMIA; HYPERLIPIDEMIA; HYPERTENSION; HYPOALBUMINEMIA; IMMOBILIZATION; INFLAMMATION; INSULIN RESISTANCE; LEUKOCYTE; LOW DRUG DOSE; MEMBRANE MICROPARTICLE; MOLECULAR INTERACTION; NONHUMAN; OBESITY; PORPHYROMONAS GINGIVALIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; RHEUMATOID ARTHRITIS; SIDE EFFECT; SMOKING; SMOKING CESSATION; STREPTOCOCCUS; SYSTEMIC LUPUS ERYTHEMATOSUS; THROMBOCYTE; THROMBOCYTE AGGREGATION; THROMBOSIS; VENOUS THROMBOEMBOLISM;

EID: 84857725142     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/138161212799504731     Document Type: Review

References (222)

1. Martinelli I, Bucciarelli P, Mannucci PM. Thrombotic risk factors: basic pathophysiology. Crit Care Med 2010; 38 (2 Suppl): S3-S9.
2. Poredos P, Jezovnik MK. The role of inflammation in venous thromboembolism and the link between arterial and venous thrombosis. Int Angiol 2007; 26: 306-311.
3. Di Minno MN, Tufano A, Ageno W, Prandoni P, Di Minno G. Identifying high-risk individuals for cardiovascular disease: similarities between venous and arterial thrombosis in perspective. A 2011 update. Intern Emerg Med 2012; 7: 9-13.
4. Lacut K, van der Maaten J, Le Gal G, Cornily G, Mottier D, Oger E. Antiplatelet drugs and risk of venous thromboembolism: results from the EDITH case-control study. Haematologica 2008; 93: 1117-1118.
5. Westerweel PE, Verhaar MC. Endothelial progenitor cell dysfunction in rheumatic disease. Nat Rev Rheumatol 2009; 5: 332-340.
6. Koc Y, Gullu I, Akpek G, et al. Vascular involvement in Behcet"s Disease. J Rheumatol 1992; 19: 402-10.
7. Seyahi E, Yurdakul S. Behçet's Syndrome and Thrombosis. Mediterr J Hematol Infect Dis 2011; 3: e2011026.
8. Merkel PA, Lo GH, Holbrook JT, et al. Wegener's Granulomatosis Etanercept Trial Research Group. Brief communication: high incidence of venous thrombotic events among patients with Wegener granulomatosis: the Wegener's Clinical Occurrence of Thrombosis (WeCLOT) Study. Ann Intern Med 2005; 142: 620-626.
9. Stassen PM, Derks RP, Kallenberg CG, Stegeman CA. Venous thromboembolism in ANCA-associated vasculitis incidence and risk factors. Rheumatology (Oxford) 2008; 47: 530-534.
10. Allenbach Y, Seror R, Pagnoux C, Teixeira L, Guilpain P, Gui-llevin L, French Vasculitis Study Group. High frequency of venous thromboembolic events in Churg-Strauss syndrome, Wegener's gra-nulomatosis and microscopic polyangiitis but not polyarteritis no-dosa: a systematic retrospective study on 1130 patients. Ann Rheum Dis 2009; 68: 564-567.
11. Sebastian JK, Voetsch B, Stone JH, et al. Wegener's Granulomatosis Etanercept Trial Research Group. The frequency of anticardiolipin antibodies and genetic mutations associated with hypercoagulability among patients with Wegener's granulomatosis with and without history of a thrombotic event. J Rheumatol 2007; 34: 2446-2450.
12. Akazawa H, Ikeda U, Yamamoto K, Kuroda T, Shimada K. Hyper-coagulable state in patients with Takayasu"s arteritis. Thromb Hae-most 1996; 75: 712-716.
13. Wolfe F, Freundlich B, Straus WL. Increase in cardiovascular and cerebrovascular disease prevalence in rheumatoid arthritis. J Rheum 2003; 30: 36-40.
14. Matta F, Singala R, Yaekoub AY, Najjar R, Stein PD. Risk of venous thromboembolism with rheumatoid arthritis. Thromb Haemost 2009; 101: 134-138.
15. Burgos PI, Alarcón GS. Thrombosis in systemic lupus erythemato-sus: risk and protection. Expert Rev Cardiovasc Ther 2009; 7: 1541-1549.
16. Palatinus A, Adams M. Thrombosis in systemic lupus erythemato-sus. Semin Thromb Hemost 2009; 35: 621-629.
17. Cervera R. Lessons from the "Euro-phospholipid" project. Auto-immun Rev 2008; 7: 174-178.
18. Ruiz-Irastorza G, Crowther M, Branch W, Khamashta MA. An-tiphospholipid syndrome. Lancet 2010; 30; 376: 1498-1509.
19. Aksu G, Ozturk C, Kavakli K, Genel F, Kutukculer N. Hypercoagulability: interaction between inflammation and coagulation in familial Mediterranean fever. Clin Rheumatol 2007; 26: 366-370.
20. Demirel A, Celkan T, Kasapcopur O, et al. Is Familial Mediterranean Fever a thrombotic disease or not? Eur J Pediatr 2008; 167: 279-285.
21. Olin JW, Shih A. Thromboangiitis obliterans (Buerger's disease). Curr Opin Rheumatol 2006; 18: 18-24.
22. Fazeli B, Rezaee A. A review on thromboangiitis obliterans patho-physiology: thrombosis and angiitis, which is to blame? Vascular 2011; 19: 141-153.
23. Jackson LM, O'Gorman PJ, O'Connell J, Cronin CC, Cotter KP, Shanahan F. Thrombosis in inflammatory bowel disease: clinical setting, procoagulant profile and factor V Leiden. QJM 1997; 90: 183-188.
24. Irwing PM, Pasi KJ, Rampton DS. Thrombosis and inflammatory bowel disease. Clin Gastroenterol Hepatol 2005; 3: 617-628.
25. Gawaz M, Langer H, May AE. Platelets in inflammation and atherogenesis. J Clin Invest 2005; 115: 3378-3384.
26. Repka-Ramirez MS, Baraniuk JN. Histamine in health and disease. Clin Allergy Immunol 2002; 17: 1-25.
27. Chen S, Springer TA. Selectin receptor-ligand bonds: Formation limited by shear rate and dissociation governed by the Bell model. Proc Natl Acad Sci USA 2001: 98: 950-955.
28. Wakefield TW, Henke PK. The Role of Inflammation in Early and Late Venous Thrombosis: Are There Clinical Implications? Semin Vasc Surg 2005; 18: 118-129.
29. Myers DD, Hawley AE, Farris DM, et al. P-selectin and leukocyte microparticles are associated with venous thrombogenesis. J Vasc Surg 2003; 38: 1075-1089.
30. Wakefield TW, Strieter RM, Prince MR, Downing LJ, Greenfield LJ. Pathogenesis of venous thrombosis: a new insight. Cardiovasc Surg 1997; 5: 6-15.
31. van der PT, Buller HR, ten Cate H, et al. Activation of coagulation after administration of tumor necrosis factor to normal subjects. N Engl J Med 1990; 322: 1622-1627.
32. Verma S, Li SH, Badiwala MV et al. Endothelin antagonism and interleukin-6 inhibition attenuate the proatherogenic effects of C-reactive protein. Circulation 2002; 105: 1890-1896.
33. Fox EA, Kahn SR. The relationship between inflammation and venous thrombosis. A systematic review of clinical studies. Thromb Haemost 2005; 94: 362-365.
34. Reitsma PH, Rosendaal FR. Activation of innate immunity in patients with venous thrombosis: the Leiden Thrombophilia Study. J Thromb Haemost 2004; 2: 619-622.
35. Van Aken BE, Reitsma PH, Rosendaal FR. Interleukin 8 and venous thrombosis: evidence for a role of inflammation in thrombosis. Br J Haematol 2002; 116: 173-177.
36. Pieroni F, Lourenço DM, Morelli VM, Maffei FH, Zago MA, Franco RF. Cytokine gene variants and venous thrombotic risk in the BRATROS (Brazilian Thrombosis Study). Thromb Res 2007; 120: 221-229.
37. Levi M, van der Poll T. Inflammation and thrombosis. Crit Care Med 2010; 38 (Suppl): S26-S34.
38. Steinhubl SR, Badimon JJ, Bhatt DL, Herbert JM, Lüscher TF. Clinical evidence for anti-inflammatory effects of antiplatelet therapy in patients with atherothrombotic disease. Vascular Medicine 2007; 12: 113-122.
39. Neumann FJ, Zohlnhofer D, Fakhoury L, Ott I, Gawaz M, Schömig A. Effect of glycoprotein IIb/IIIa receptor blockade on platelet-leukocyte interaction and surface expression of the leukocyte in-tegrin Mac-1 in acute myocardial infarction. J Am Coll Cardiol 1999; 34: 1420-1426.
40. Wakefield TW, Myers DD, Henke PK. Mechanisms of Venous Thrombosis and Resolution. Arterioscler Thromb Vasc Biol 2008; 28: 387-391.
41. Palareti G, Cosmi B, Legnani C, et al. D-dimer testing to determine the duration of anticoagulation therapy. N Engl J Med 2006; 355: 1780-1789.
42. van Hinsbergh VW. Endothelium-role in regulation of coagulation and inflammation. Semin Immunopathol 2012; 34(1): 93-106.
43. Ross R. Atherosclerosis: An inflammatory disease. N Engl J Med 1999; 340: 115-26.
44. Garlanda C, Dejana E. Heterogeneity of endothelial cells: Specific markers. Arterioscler Thromb Vasc Biol 1997; 17: 1193-1202.
45. May AE, Langer H, Seizer P, Bigalke B, Lindemann S, Gawaz M. Platelet-leukocyte interactions in inflammation and atherothrombo-sis. Semin Thromb Hemost 2007; 33: 123-127.
46. Shi G, Morrell CN. Platelets as initiators and mediators of inflammation at the vessel wall. Thromb Res 2011; 127: 387-390.
47. Nurden AT. Platelets, inflammation and tissue regeneration. Thromb Haemost 2011; 105 Suppl 1: S13-S33.
48. Bhargava S, Parakh R, Manocha A, Ali A, Srivastava LM. Prevalence of hyperhomocysteinemia in vascular disease: comparative study of thrombotic venous disease vis-à-vis occlusive arterial disease. Vascular 2007; 15: 149-153.
49. Belton OA, Duffy A, Toomey S, Fitzgerald DJ. Cyclooxygenase isoforms and platelet vessel wall interactions in the apolipoprotein E knockout mouse model of atherosclerosis. Circulation 2003; 108: 3017-3023.
50. Schror K. The effect of prostaglandins and thromboxane A2 on coronary vessel tone-mechanisms of action and therapeutic implications. Eur Heart J Nov 1993; 14 (Suppl I): 34-41.
51. Schiemann F, Grimm TA, Hoch J, et al. Mast cells and neutrophils proteolytically activate chemokine precursor CTAP-III and are subject to counterregulation by PF-4 through inhibition of chymase and cathepsin G. Blood 2006; 107: 2234-2242.
52. Libby P, Warner SJ, Friedman GB. Interleukin 1: a mitogen for human vascular smooth muscle cells that induces the release of growth-inhibitory prostanoids. J Clin Invest Feb 1988; 81: 487-498.
53. Yoshizumi M, Kurihara H, Morita T, et al. Interleukin 1 increases the production of endothelin-1 by cultured endothelial cells. Bio-chem Biophys Res Commun 1990; 166: 324-329.
54. Gasparyan AY, Ayvazyan L, Mikhailidis DP, Kitas GD. Mean Platelet Volume: A Link between Thrombosis and Inflammation? Curr Pharm Des 2011; 17: 47-58.
55. Thompson CB. From precursor to product: how do megakaryocytes produce platelets? Prog Clin Biol Res 1986; 215: 361-371.
56. Thompson CB, Jakubowski JA. The pathophysiology and clinical relevance of platelet heterogeneity. Blood 1988; 72: 1-8.
57. Yilmaz MB, Saricam E, Biyikoglu SF, et al. Mean platelet volume and exercise stress test. J Thromb Thrombolysis 2004; 17: 115-120.
58. Bakovic D, Pivac N, Eterovic D, et al. Changes in platelet size and spleen volume in response to selective and non-selective be-taadrenoceptor blockade in hypertensive patients. Clin Exp Pharmacol Physiol 2009; 36: 441-446.
59. Palabrica T, Lobb R, Furie BC, et al. Leukocyte accumulation promoting fibrin deposition is mediated in vivo by P-selectin on adherent platelets. Nature 1992; 359: 848-851.
60. Celi A, Pellegrini G, Lorenzet R, et al. P-selectin induces the expression of tissue factor on monocytes. Proc Natl Acad Sci USA 1994; 91: 8767-8771.
61. Italiano JE, Mairuhu ATA, Flaumenhaft R. Clinical relevance of microparticles from platelets and megakaryocytes. Curr Opin He-matol 2010: 17: 578-584.
62. Flaumenhaft R, Mairuhu ATA, Italiano JE. Platelet- and Megakar-yocyte-Derived Microparticles. Semin Thromb Hemost 2010; 36: 881-887.
63. George JN, Thoi LL, McManus LM, Reimann TA. Isolation of human platelet membrane microparticles from plasma and serum. Blood 1982; 60: 834-840.
64. George JN, Pickett EB, Saucerman S, et al. Platelet surface glyco-proteins. Studies on resting and activated platelets and platelet membrane microparticles in normal subjects, and observations in patients during adult respiratory distress syndrome and cardiac surgery. J Clin Invest 1986; 78: 340-348.
65. Horstman LL, Ahn YS. Platelet microparticles: a wide-angle perspective. Crit Rev Oncol Hematol 1999; 30: 111-142.
66. Joop K, Berckmans RJ, Nieuwland R, et al. Microparticles from patients with multiple organ dysfunction syndrome and sepsis support coagulation through multiple mechanisms. Thromb Haemost 2001; 85: 810-820.
67. Berckmans RJ, Neiuwland R, Boing AN, Romijn FP, Hack CE, Sturk A. Cell-derived microparticles circulate in healthy humans and support low grade thrombin generation. Thromb Haemost 2001; 85: 639-646.
68. Flaumenhaft R. Formation and fate of platelet microparticles. Blood Cells Mol Dis 2006; 36: 182-187.
69. Rand ML, Wang H, Bang KW, Packham MA, Freedman J. Rapid clearance of procoagulant platelet derived microparticles from the circulation of rabbits. J Thromb Haemost 2006; 4: 1621-1623.
70. Hughes M, Hayward CP, Warkentin TE, Horsewood P, Chorneyko KA, Kelton JG. Morphological analysis of microparticle generation in heparin-induced thrombocytopenia. Blood 2000; 96: 188-194.
71. Mallat Z, Benamer H, Hugel B, et al. Elevated levels of shed membrane microparticles with procoagulant potential in the peripheral circulating blood of patients with acute coronary syndromes. Circulation 2000; 101: 841-843.
72. Lee YJ, Jy W, Horstman LL, et al. Elevated platelet microparticles in transient ischemic attacks, lacunar infarcts, and multiinfarct dementias. Thromb Res 1993; 72: 295-304.
73. Galli M, Grassi A, Barbui T. Platelet-derived microvesicles in thrombotic thrombocytopenic purpura and hemolytic uremic syndrome. Thromb Haemost 1996; 75: 427-431.
74. Tomer A, Harker LA, Kasey S, Eckman JR. Thrombogenesis in sickle cell disease. J Lab Clin Med 2001; 137: 398-407.
75. Ando M, Iwata A, Ozeki Y, Tsuchiya K, Akiba T, Nihei H. Circulating platelet-derived microparticles with procoagulant activity may be a potential cause of thrombosis in uremic patients. Kidney Int 2002; 62: 1757-1763.
76. Varon D, Shai E. Role of platelet-derived microparticles in angio-genesis and tumor progression. Discov Med 2009; 8: 237-241.
77. Boilard E, Nigrovic PA, Larabee K, et al. Platelets amplify inflammation in arthritis via collagen-dependent microparticle production. Science 2010; 327: 580-583.
78. Rozmyslowicz T, Majka M, Kijowski J, et al. Platelet- and mega-karyocyte derived microparticles transfer CXCR4 receptor to CXCR4-null cells and make them susceptible to infection by X4-HIV. AIDS 2003; 17: 33-42.
79. Tan KT, Lip GY. The potential role of platelet microparticles in atherosclerosis. Thromb Haemost 2005; 94: 488-492.
80. Kim HK, Song KS, Chung JH, Lee KR, Lee SN. Platelet micropar-ticles induce angiogenesis in vitro. Br J Haematol 2004; 124: 376-384.
81. Al-Nedawi K, Meehan B, Micallef J, et al. Intercellular transfer of the oncogenic receptor EGFRvIII by microvesicles derived from tumour cells. Nat Cell Biol 2008; 10: 619-624.
82. Corrales-Medina VF, Simkins J, Chirinos JA, et al. Increased levels of platelet microparticles in HIV-infected patients with good response to highly active antiretroviral therapy. J Acquir Immune De-fic Syndr 2010; 54: 217-218.
83. Ratajczak J, Wysoczynski M, Hayek F, Janowska-Wieczorek A, Ratajczak MZ. Membrane-derived microvesicles: important and underappreciated mediators of cell-to-cell communication. Leukemia 2006; 20: 1487-1495.
84. Lippi G, Emmanuel J. Favaloro EJ, Montagnana M, Franchini M. C-reactive protein and venous thromboembolism: causal or casual association? Clin Chem Lab Med 2010; 48: 1693-1701.
85. Volanakis JE. Human C-reactive protein: expression, structure, and function. Mol Immunol 2001; 38: 189-197.
86. Szalai AJ, Agrawal A, Greenhough TJ, Volanakis JE. C-reactive protein: structural biology and host defense function. Clin Chem Lab Med 1999; 37: 265-270.
87. Pepys MB, Hirschfield GM. C-reactive protein: a critical update. J Clin Invest 2003; 111: 1805-1812.
88. Song C, Shen Y, Yamen E, et al. Serum amyloid A may potentiate prothrombotic and proinflammatory events in acute coronary syndromes. Atherosclerosis 2009; 202: 596-604.
89. Yaron G, Brill A, Dashevsky O, et al. C-reactive protein promotes platelet adhesion to endothelial cells: a potential pathway in atherothrombosis. Br J Haematol 2006; 134: 426-431.
90. Wu J, Stevenson MJ, Brown JM, Grunz EA, Strawn TL, Fay WP. C-reactive protein enhances tissue factor expression by vascular smooth muscle cells: mechanisms and in vivo significance. Arterio-scler Thromb Vasc Biol 2008; 28: 698-704.
91. Folsom AR, Lutsey PL, Astor BC, Cushman M. C-reactive protein and venous thromboembolism. A prospective investigation in the ARIC cohort. Thromb Haemost 2009; 102: 615-619.
92. Maraha B, Peeters MF, van Aken BE, den Heijer M. Chlamydia pneumoniae, systemic inflammation and the risk of venous thrombosis. Diagn Microbiol Infect Dis 2002; 42: 153-157.
93. Netea MG, Selzman CH, Kullberg BJ, et al. Acellular components of Chlamydia pneumoniae stimulate cytokine production in human blood mononuclear cells. European Journal of Immunology 2000; 30: 541-549.
94. Kaukoranta-Tolvanen SS, Teppo AM, Laitinen K, Saikku P, Linna-vuori K, Leinonen M. Growth of Chlamydia pneumonia in cultured human peripheral blood mononuclear cells and induction of cyto-kine response. Microbial Pathogenesis 1996; 21: 215-221.
95. Chen YW, Iwai T, Umeda M, et al. Elevated IgG titers to periodon-tal pathogens related to Buerger disease. Int J Cardiol. 2007; 122: 79-81.
96. Mumcu G, Ergun T, Inanc N, et al. Oral health is impaired in Be-hçet's disease and is associated with disease severity. Rheumatology (Oxford) 2004; 43: 1028-1033.
97. Mumcu G, Ergun T, Elbir Y, et al. Clinical and immunological effects of azithromycin in Behçet's disease. J Oral Pathol Med 2005; 34: 13-16.
98. Fischer MJ, Rauch J, Levine JS. The antiphospholipid syndrome. Semin Nephrol 2007; 27: 35-46.
99. Eichhorn J, Sima D, Lindschau C, et al. Antiendothelial cell antibodies in thromboangiitis obliterans. A J Med Sci 1998; 315: 17-23.
100. Kallenberg CG. Pathophysiology of ANCA-associated small vessel vasculitis. Curr Rheumatol Rep 2010; 12: 399-405.
101. Llach F, Papper S, Massry SG. The clinical spectrum of renal vein thrombosis: acute and chronic. Am J Med 1980; 69: 819-827.
102. Llach F. Hypercoagulability, renal vein thrombosis, and other thrombotic complications of nephrotic syndrome. Kidney Int 1985; 28: 429-439.
103. Velasquez Forero F, Garcia Prugue N, Ruiz Morales N. Idiopathic nephrotic syndrome of the adult with asymptomatic thrombosis of the renal vein. Am J Nephrol 1988; 8: 457-462.
104. Lilova MI, Velkovski IG, Topalov IB. Thromboembolic complications in children with nephrotic syndrome in Bulgaria (1974-1996). Pediatr Nephrol 2000; 15: 74-78.
105. Singhal R, Brimble KS. Thromboembolic complications in the nephrotic syndrome: pathophysiology and clinical management. Thromb Res 2006; 118: 397-407.
106. Kayali F, Najjar R, Aswad F, Matta F, Stein PD. Venous throm-boembolism in patients hospitalized with nephrotic syndrome. Am J Med 2008; 121: 226-230.
107. Mahmoodi BK, ten Kate MK, Waanders F, et al. High absolute risks and predictors of venous and arterial thromboembolic events in patients with nephrotic syndrome: results from a large retrospective cohort study. Circulation 2008; 117: 224-230.
108. Mahmoodi BK, Gansevoort RT, Veeger NJ, et al. Microalbuminu-ria and risk of venous thromboembolism. JAMA 2009; 301: 1790-1797.
109. Wattanakit K, Cushman M. Chronic kidney disease and venous thromboembolism: epidemiology and mechanisms. Curr Opin Pulm Med 2009; 15: 408-412.
110. The Atherosclerosis Risk in Communities (ARIC) Study Investigators. The Atherosclerosis Risk in Communities (ARIC) Study: design and objectives. The ARIC investigators. Am J Epidemiol 1989; 129: 687-702.
111. Fried LP, Borhani NO, Enright P, et al. The Cardiovascular Health Study: design and rationale. Ann Epidemiol 1991; 1: 263-276.
112. Tell GS, Fried LP, Hermanson B, Manolio TA, Newman AB, Borhani NO. Recruitment of adults 65 years and older as participants in the Cardiovascular Health Study. Ann Epidemiol 1993; 3: 358-366.
113. Coughlin SR. Thrombin signaling and protease- activated receptors. Nature 2000; 407: 258-264.
114. van der Poll T, de Jonge E, Levi M. Regulatory role of cytokines in disseminated intravascular coagulation. Semin Thromb Hemost 2001; 27: 639-651.
115. Szaba FM, Smiley ST. Roles for thrombin and fibrin (ogen) in cytokine/chemokine production and macrophage adhesion in vivo. Blood 2002; 99: 1053-1059.
116. Peerschke EIB, Yin W, Ghebrehiwet B. Platelet mediated complement activation. Adv Exp Med Biol 2008; 632: 81-91.
117. Levi M, van der Poll T. Inflammation and coagulation. Crit Care Med. 2010; 38 (2 Suppl): S26-S34.
118. Faioni EM, Cattaneo M. Inflammation and thrombosis-brothers in arms. European Oncology & Haematology 2011; 7: 81-84.
119. Yazici Y, Yurdakul S, Yazici H. Behçet's syndrome. Curr Rheumatol Rep 2010; 12: 429-435.
120. Donmez A, Aksu K, Celik HA, et al. Thrombin activatable fibrinolysis inhibitor in Behcet's disease. Thromb Res 2005; 115: 287-292.
121. Yurdakul S, Hekim N, Soysal T, et al. Fibrinolytic activity and d-dimer levels in Behçet's syndrome. Clin Exp Rheumatol 2005; 23 (4 Suppl 38): S53-S58.
122. Leiba M, Seligsohn U, Sidi Y, et al. Thrombophilic factors are not the leading cause of thrombosis in Behcet's disease. Ann Rheum Dis 2004; 63: 1445-1449.
123. Pay S, Simşek I, Erdem H, Dinç A. Immunopathogenesis of Behçet's disease with special emphasize on the possible role of antigen presenting cells. Rheumatol Int 2007; 27: 417-424.
124. Kayikçioglu M, Aksu K, Hasdemir C, et al. Endothelial functions in Behçet's disease. Rheumatol Int 2006; 26: 304-308.
125. Oflaz H, Mercanoglu F, Karaman O, et al. Impaired endothelium-dependent flow-mediated dilation in Behçet's disease: more prominent endothelial dysfunction in patients with vascular involvement. Int J Clin Pract 2005; 59: 777-781.
126. Atagunduz P, Ergun T, Direskeneli H. MEFV mutations are increased in Behçet's disease (BD) and are associated with vascular involvement. Clin Exp Rheumatol 2003; 21(4 Suppl 30): S35-S37.
127. Rabinovich E, Shinar Y, Leiba M, Ehrenfeld M, Langevitz P, Liv-neh A. Common FMF alleles may predispose to development of Behcet's disease with increased risk for venous thrombosis. Scand J Rheumatol 2007; 36: 48-52.
128. Mumcu G, Inanc N, Yavuz S, Direskeneli H. The role of infectious agents in the pathogenesis, clinical manifestations and treatment strategies in Behçet's disease. Clin Exp Rheumatol 2007; 25 (4 Suppl 45): S27-S33.
129. Gul A. Behçet's disease: an update on the pathogenesis. Clin Exp Rheumatol 2001; 19 (5 Suppl 24): S6-S12.
130. Demirkesen C, Oz B, Goksel S. Histopathology of Behçet's syndrome. In Yazici Y, Yazici H (eds) Behçet's Syndrome, 1th edn, New York, Springer, 2010; pp 215-242.
131. Kobayashi M, Ito M, Nakagawa A, et al. Neutrophil and endothelial cell activation in the vasa vasorum in vasculo-Behçet disease. Histopathology 2000; 36: 362-371.
132. Ahn JK, Lee YS, Jeon CH, Koh EM, Cha HS. Treatment of venous thrombosis associated with Behcet's disease: immunosuppressive therapy alone versus immunosuppressive therapy plus anticoagulation. Clin Rheumatol 2008; 27: 201-205.
133. Garcia G, Achouh L, Cobarzan D, Fichet D, Humbert M. Severe venous thromboembolic disease in Churg-Strauss syndrome. Allergy 2005; 60: 409-410.
134. Weidner S, Hafezi-Rachti S, Rupprecht HD. Thromboembolic events as a complication of antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum. 2006; 55: 146-149.
135. Ames PR, Margaglione M, Mackie S, Alves JD. Eosinophilia and thrombophilia in Churg Strauss Syndrome: a clinical and pathogenetic overview. Clin Appl Thromb Hemost 2010; 16: 628-636.
136. De Bandt M, Meyer O, Dacosta L, Elbim C, Pasquier C. Antiproteinase-3 (PR3) antibodies (C-ANCA) recognize various targets on the human umbilical vein endothelial cell (HUVEC) membrane. Clin Exp Immunol 1999; 115: 362-368.
137. Marzano AV, Tedeschi A, Rossio R, Fanoni D, Cugno M. Prothrombotic State in Churg-Strauss Syndrome: A Case Report. J Investig Allergol Clin Immunol 2010; 20: 616-619.
138. Mason JC. Takayasu arteritis advances in diagnosis and management. Nat Rev Rheumatol 2010; 6: 406-415.
139. Arnaud L, Haroche J, Mathian A, Gorochov G, Amoura Z. Pathogenesis of Takayasu's arteritis: A 2011 update. Autoimmun Rev 2011; 11: 61-67.
140. Wiatr E, Dobkowski P, Opoka L, et al. Wegener's granulomatosis overlapped with Takayasu arteritis complicated by thrombosis of the internal jugular vein. Pneumonol Alergol Pol 2003; 71: 440-448.
141. Purkayastha S, Jayadevan ER, Kapilamoorthy TR, Gupta AK. Suction thrombectomy of thrombotic occlusion of the subclavian artery in a case of Takayasu's arteritis. Cardiovasc Intervent Radiol 2006; 29: 289-293.
142. Misra R, Aggarwal A, Chag M, Sinha N, Shrivastava S. Raised anticardiolipin antibodies in Takayasu's arteritis. Lancet 1994; 343: 1644-1645.
143. Park MC, Park YB, Jung SY, Lee KH, Lee SK. Anti-endothelial cell antibodies and antiphospholipid antibodies in Takayasu's arteri-tis: correlations of their titers and isotype distributions with disease activity. Clin Exp Rheumatol 2006; 24 (2 Suppl 41): S10-S16.
144. Mameli A, Barcellona D, Marongiu F. Rheumatoid arthritis and thrombosis. Clin Exp Rheumatol 2009; 27: 846-855.
145. Liang KP, Liang KV, Matteson EL, McClelland RL, Christianson TJ, Turesson C. Incidence of noncardiac vascular disease in rheumatoid arthritis and relationship to extraarticular disease manifestations. Arthritis Rheum 2006; 54: 642-648.
146. Dhavvan SS, Quyyumi AA. Rheumatoid arthritis and cardiovascular disease. Curr Atheroscler 2008; 10: 128-133.
147. Ageno W, Squizzato A, Ambrosini F. Thrombosis prophylaxis in medical patients: a retrospective review of clinical practice patterns. Hematologica 2002; 87: 746-750.
148. Alikhan R, Cohen AT, Combe S, et al. Medenox Study. Risk factors for venous thromboembolism in hospitalized patients with acute medical illness: analysis of the MEDENOX Study. Arch Intern Med 2004; 164: 963-968.
149. Sikorskj JM, Hampson WG, Staddon GE. The natural history and etiology of deep vein thrombosis after total hip replacement. J Bone joint Surg Br 1981; 63: 171-177.
150. van Heereveld HA, Laan RF, van de Hoogen FH, Malefijt MC, Novakova IR, van de Putte LB. Prevention of symptomatic thrombosis with short term (low molecular weight) heparin in patients with rheumatoid arthritis after hip or knee replacement. Ann Rheum Dis 2001; 60: 974-976.
151. Zacharski LR, Brown FE, Memoli VA, et al. Pathways of coagulation activation in situ in rheumatoid synovial tissue. Clin Immunol Immunopathol 1992; 63: 155-162.
152. Berkmans RJ, Nieuwland R, Tak PP. Cell-derived microparticles in synovial fluid from inflamed arthritic joints support coagulation exclusively via a factor VII-dependent mechanism. Arthritis Rheum 2002; 46: 3857-3866.
153. Siren AL, McCarron R, Wang L, et al. Proinflammatory cytokine expression contributes to brain injury provoked by chronic mono-cyte activation. Mol Med 2001; 7: 219-229.
154. Grignani G, Maiolo A. Cytokines and haemostasis. Haematologica 2000; 85: 967-972.
155. Solomon DH, Goodson NJ, Katz JN et al. Pattern of cardiovascular risk in rheumatoid arthritis. Ann Rheum Dis 2006; 65: 1608-1612.
156. Wallace DJ, Linker-Israeli M, Metzger AL, Stecher VJ. The relevance of antimalarial therapy with regard to thrombosis, hypercho-lesterolemia and cytokines in SLE. Lupus 1993; 2 (Suppl. 1): S13-S15.
157. Somers E, Magder LS, Petri M. Antiphospholipid antibodies and incidence of venous thrombosis in a cohort of patients with systemic lupus erythematosus. J Rheumatol 2002; 29: 2531-2536.
158. Sallai KK, Nagy E, Bodo I, Mohl A, Gergely P. Thrombosis risk in systemic lupus erythematosus: the role of thrombophilic risk factors. Scand J Rheumatol 2007; 36: 198-205.
159. Martínez-Berriotxoa A, Ruiz-Irastorza G, Egurbide MV, Rueda M, Aguirre C. Homocysteine, antiphospholipid antibodies and risk of thrombosis in patients with systemic lupus erythematosus. Lupus 2004; 13: 927-933.
160. Lockshin MD, Derksen RH. New developments in lupus-associated antiphospholipid syndrome. Lupus 2008; 17: 443-446.
161. El-Magadmi M, Bodill H, Ahmad Y, et al. Systemic lupus erythematosus: an independent risk factor for endothelial dysfunction in women. Circulation 2004; 110: 399-404.
162. Svenungsson E, Cederholm A, Jensen-Urstad K, Fei GZ, de Faire U, Frostegård J. Endothelial function and markers of endothelial activation in relation to cardiovascular disease in systemic lupus erythematosus. Scand J Rheumatol 2008; 37: 352-359.
163. Piper MK, Raza K, Nuttall SL, et al. Impaired endothelial function in systemic lupus erythematosus. Lupus 2007; 16: 84-88.
164. Salmon JE, de Groot PG. Pathogenetic role of antiphosholipid antibodies. Lupus 2008; 17: 405-411.
165. Robak E, Sysa-Jedrzejewska A, Robak T. Vascular endothelial growth factor and its soluble receptors VEGFR-1 and VEGFR-2 in the serum of patients with systemic lupus erythe-matosus. Mediators Inflamm 2003; 12: 293-298.
166. Reynolds HR, Buyon J, Kim M, et al. Association of plasma soluble E-selectin and adiponectin with carotid plaque in patients with systemic lupus erythematosus. Atherosclerosis 2010; 210: 569-574.
167. Giron-Gonzalez JA, Garcia del Rio E, Rodriguez C, Rodriguez-Martorell J, Serrano A. Antiphospholipid syndrome and asymptomatic carriers of antiphospholipid antibody: prospective analysis of 404 individuals. J Rheumatol 2004; 31: 1560-1567.
168. Biggioggero M, Meroni PL. The geoepidemiology of the antiphospholipid antibody syndrome. Autoimmun Rev 2010; 9: A299-A304.
169. Finazzi G. The epidemiology of the antiphospholipid syndrome: who is at risk? Curr Rheumatol Rep 2001; 3: 271-276.
170. Vega-Ostertag ME, Pierangeli SS. Mechanisms of aPL-mediated thrombosis: effects of aPL on endothelium and platelets. Curr Rheumatol Rep 2007; 9: 190-197.
171. Degroot PG, Derksen RH. Protein C pathway, antiphospholipid and thrombosis. Lupus 1994; 3: 229-233.
172. Tanne D, Katzav A, Beilin O, et al. Interaction of inflammation, thrombosis, aspirin and enoxaparin in CNS experimental antiphospholipid syndrome. Neurobiol Dis 2008; 30: 56-64.
173. Lim W. Complement and the antiphospholipid syndrome. Curr Opin Hematol 2011; 18: 361-365.
174. Pierangeli SS, Vega-Ostertag ME, González EB. New targeted therapies for treatment of thrombosis in antiphospholipid syndrome. Expert Rev Mol Med 2007; 13; 9: 1-15.
175. Aoun EG, Musallam KM, Uthman I, Beydoun A, El-Hajj T, Taher AT. Childhood stroke in a child with familial Mediterranean fever carrying several prothrombotic risk factors. Lupus 2009; 18: 845-847.
176. Satoh S, Itoh C, Nakamura N. A case of frosted branch angiitis associated with retinal vein occlusion as a complication of familial Mediterranean fever. Nihon Ganka Gakkai Zasshi 2010; 114: 621-628.
177. Sari S, Egritas O, Bukulmez A, Dalgic B, Soylemezoglu O. Is familial Mediterranean fever a possible cofactor for Budd-Chiari syndrome? J Pediatr Gastroenterol Nutr 2009; 49: 481-484.
178. Onen F. Familial Mediterranean fever. Rheumatol Int 2006; 26: 489-496.
179. Aksu K, Keser G. Coexistence of vasculitides with Familial Mediterranean Fever. Rheumatol Int 2011; 31: 1263-1274.
180. Akdogan A, Calguneri M, Yavuz B, et al. Are familial Mediterranean fever (FMF) patients at increased risk for atherosclerosis? Impaired endothelial function and increased intima media thickness are found in FMF. J Am Coll Cardiol 2006; 48: 2351-2353.
181. Terekeci HM, Oktenli C, Ozgurtas T, et al. Increased asymmetric dimethylarginine levels in young men with familial Mediterranean fever (FMF): is it early evidence of interaction between inflammation and endothelial dysfunction in FMF? J Rheumatol 2008; 35: 2024-2029.
182. Puéchal X, Fiessinger JN. Thromboangiitis obliterans or Buerger's disease: challenges for the rheumatologist. Rheumatology (Oxford) 2007; 46: 192-199.
183. Arkkila PE. Thromboangiitis obliterans (Buerger's disease). Or-phanet J Rare Dis 2006; 27; 1-5.
184. de Godoy JMP, Braile DM, Godoy MF. Buerger"s disease and anticardiolipin antibodies: a worse prognosis? Clin Appl Thrombosis Hemostasis 2002; 8: 85-86.
185. Iwai T, Inoue Y, Umeda M, et al. Oral bacteria in the occluded arteries of patients with Buerger disease. J Vasc Surg 2005; 42: 107-115.
186. Malecki R, Zdrojowy K, Adamiec R. Thromboangiitis obliterans in the 21st century a new face of disease. Atherosclerosis 2009; 206: 328-334.
187. Grainge MJ, West J, Card TR. Venous thromboembolism during active disease and remission in inflammatory bowel disease: a cohort study. Lancet 2010; 375: 657-663.
188. Ha C, Magowan S, Accortt NA, Chen J, Stone CD. Risk of arterial thrombotic events in inflammatory bowel disease. Am J Gastroenterol 2009; 104: 1445-1451.
189. Faioni EM, Ferrero S, Fontana G, et al. Expression of endothelial protein C receptor and thrombomodulin in the intestinal tissue of patients with inflammatory bowel disease. Crit Care Med 2004; 32 (5 Suppl): S266-S70.
190. Miehsler W, Reinisch W, Valic E, et al. Is inflammatory bowel disease an independent and disease specific risk factor for thromboembolism? Gut 2004; 53: 542-548.
191. Young E. The anti inflammatory effects of heparin and related compounds. Thromb Res 2008; 122: 743-752.
192. Sowa JM, Crist SA, Racliff TL, Elzey BD. Platelet influence on T and B cell responses. Arch Immunol Ther Exp (Warsz). 2009; 57: 235-241.
193. Hamuryudan V, Ozyazgan Y, Hizli N, et al. Azathioprine in Behcet's syndrome: effects on long-term prognosis. Arthritis Rheum 1997; 40: 769-774.
194. Kural-Seyahi E, Fresko I, Seyahi N, et al. The long-term mortality and morbidity of Behçet syndrome: a 2-decade outcome survey of 387 patients followed at a dedicated center. Medicine (Baltimore) 2003; 82: 60-76.
195. Chande N, McDonald JW, Macdonald JK, Wang JJ. Unfractionated or low-molecular weight heparin for induction of remission in ul-cerative colitis. Cochrane Database Syst Rev 2010: 6: CD006774.
196. Hurlimann D, Forster A, Noll G, et al. Anti-tumor necrosis factor-alpha treatment improves endothelial function in patients with rheumatoid arthritis. Circulation 2002; 106: 2184-2187.
197. Gonzalez-Juanatey C, Llorca J, Sanchez-Andrade A, Garcia-Porrua C,Martin J, Gonzalez-Gay MA. Short term adalimumab therapy improves endothelial function in patients with rheumatoid arthritis refractory to infliximab. Clin Exp Rheumatol 2006; 24: 309-312
198. Geiler J, Buch M, McDermott MF. Anti-TNF treatment in Rheumatoid Arthritis. Curr Pharm Des 2011; 17: 3141-3154.
199. Petitpain N, Gambier N, Wahl D, Chary-Valckenaere I, Loeuille D, Gillet P; French Network of Pharmacovigilance Centers. Arterial and venous thromboembolic events during anti-TNF therapy: a study of 85 spontaneous reports in the period 2000-2006. Biomed Mater Eng 2009; 19: 355-364.
200. Korswagen LA, Bartelds GM, Krieckaert CL, et al. Venous and arterial thromboembolic events in adalimumab-treated patients with antiadalimumab antibodies: a case series and cohort study. Arthritis Rheum 2011; 63: 877-883.
201. Gasparyan AY, Stavropoulos-Kalinoglou A, Mikhailidis DP, Toms TE, Douglas KM, Kitas GD. The rationale for comparative studies of accelerated atherosclerosis in rheumatic diseases. Curr Vasc Pharmacol 2010; 8: 437-449.
202. Steinhubl SR, Schneider DJ, Berger PB, et al. Determining the efficacy of antiplatelet therapies for the individual: lessons from clinical trials. J Thromb Thrombolysis 2008; 26: 8-13.
203. Steinhubl SR, Berger PB. Aspirin following PCI: too much of a good thing? Eur Heart J 2009; 30: 882-884.
204. Gasparyan AY. Platelets in inflammation and thrombosis. Inflamm Allergy Drug Targets 2010; 9: 319-321.
205. Acikel S, Akdemir R. The relationship between inflammation, platelet activation and antiplatelet resistance. Inflamm Allergy Drug Targets 2010; 9: 364-381.
206. Gasparyan AY, Watson T, Lip GY. The role of aspirin in cardiovascular prevention: implications of aspirin resistance. J Am Coll Cardiol 2008; 51: 1829-1843.
207. Chakraborty K, Khan GA, Banerjee P, Ray U, Sinha AK. Inhibition of human blood platelet aggregation and the stimulation of nitric oxide synthesis by aspirin. Platelets 2003; 14: 421-427.
208. Cho JY. Immunomodulatory effect of nonsteroidal anti-inflammatory drugs (NSAIDs) at the clinically available doses. Arch Pharm Res 2007; 30: 64-74.
209. Weyand CM, Kaiser M, Yang H, Younge B, Goronzy JJ. Therapeutic effects of acetylsalicylic acid in giant cell arteritis. Arthritis Rheum 2002; 46: 457-466.
210. Weyand CM, Goronzy JJ. Medium- and large-vessel vasculitis. N Engl J Med 2003; 349: 160-169.
211. Gasparyan AY. Inflammation thrombosis and vascular biology: translating ideas into cardiovascular research and therapy. Open Cardiovasc Med J 2010; 4: 20-22.
212. Gasparyan AY, Stavropoulos-Kalinoglou A, Mikhailidis DP, Douglas KM, Kitas GD. Platelet function in rheumatoid arthritis: arthritic and cardiovascular implications. Rheumatol Int 2011; 31: 153-164.
213. Yüksel S, Ayvazyan L, Gasparyan AY. Familial Mediterranean Fever as an emerging clinical model of atherogenesis associated with low-grade inflammation. Open Cardiovasc Med J 2010; 4: 51-56.
214. Gajos G, Rostoff P, Undas A, Piwowarska W. Effects of Effects of polyunsaturated omega-3 fatty acids on responsiveness to dual anti-platelet therapy in patients undergoing percutaneous coronary intervention: the OMEGA-PCI (OMEGA-3 fatty acids after pci to modify responsiveness to dual antiplatelet therapy) study. J Am Coll Cardiol. 2010; 55: 1671-1678.
215. Acikel S, Akdemir R, Cagirci G, Yesilay AB, Dogan M, Kilic H. The treatment of clopidogrel resistance: triple antiplatelet therapy and future directions. Int J Cardiol 2010; 144: 79-82.
216. Hatoum OA, Binion DG. The vasculature and inflammatory bowel disease: contribution to pathogenesis and clinical pathology. In-flamm Bowel Dis 2005; 11: 304-313.
217. Vignoli A, Marchetti M, Balducci D, Barbui T, Falanga A. Differential effect of the low-molecular-weight heparin, dalteparin, and unfractionated heparin on microvascular endothelial cell haemostatic properties. Haematologica 2006; 91: 207-214.
218. Kozlowski EO, Pavao MSG, Bors IG. Ascidian dermatan sulfates attenuate metastasis, inflammation and thrombosis by inhibition of P-selectin. J Thromb Haemost 2011; 9: 1807-1815.
219. Marques-da-Silva C, Chaves MM, Castro NG, Coutinho-Silva R, Guimaraes MZ. Colchicine inhibits cationic dye uptake induced by ATP in P2X2 and P2X7 receptor-expressing cells: implications for its therapeutic action. Br J Pharmacol 2011; 163: 912-926.
220. Ramcharan AS, Van Stralen KJ, Snoep JD, Mantel-Teeuwisse AK, Rosendaal FR, Doggen CJ. HMG-CoA reductase inhibitors, other lipid-lowering medication, antiplatelet therapy, and the risk of venous thrombosis J Thromb Haemost 2009; 7: 514-520.
221. Rand J, Wu X, Quinn A, Chen PP, Hathcock JJ, Taatjes DJ. Hydroxychloroquine directly reduces the binding of antiphos-pholipid antibody-p2-glycoprotein I complexes to phospholipid bilayers. Blood 2008; 112: 1687-1695.
222. Piazza G, Creager MA. Thromboangiitis Obliterans. Circulation 2010; 121: 1858-1861.